Core Insights - The launch event of SILKROSE® in Beijing highlighted the innovative advancements in light medical beauty technology, featuring key industry experts and marking the introduction of the first domestically produced PEG cross-linked hyaluronic acid gel with complete independent intellectual property rights [1][8] Group 1: Product Innovation - The PEG cross-linking technology of SILKROSE® was a focal point, offering a more complex three-dimensional network structure compared to traditional products, which enhances flexibility and prevents displacement and deformation [2] - The safety design of the product is noteworthy, as the PEG fragments released after hyaluronic acid degradation can be completely metabolized in the body, eliminating accumulation risks and addressing traditional cross-linking agents' metabolic concerns [4] - Clinical data indicates that the effects of SILKROSE® can last over 9 months, achieving a balance between "natural dynamism" and "long-lasting safety" [4] Group 2: Industry Perspectives - Experts emphasized the broad application prospects of PEG cross-linking technology in the medical beauty field, with a commitment from the company to pursue technological innovation and product quality [5] - A roundtable discussion among leading medical beauty experts focused on the comprehensive evaluation system for new technologies and materials in facial rejuvenation injection treatments, highlighting a shift in the market from "incremental competition" to "quality competition" [7] Group 3: Strategic Partnerships - A strategic cooperation agreement was signed between the company and China Resources Shanghai, aiming to leverage channel advantages for accelerated market coverage of the new product [8] - Since its listing in 2020, the company has supported the development and production of various PEG-modified drugs and medical devices, both domestically and internationally [8] Group 4: Future Outlook - With the official launch of SILKROSE® and subsequent market promotion, the company aims to empower medical beauty institutions through material innovation, providing safer and higher-quality options for consumers [10]

8月16日，SILKROSE丝玫瑰新品发布会在北京盛大举行并圆满落幕。这场聚焦轻医美技术创新的行业 盛会，汇聚了医美专家、学者、主流媒体及跨界嘉宾。中整协新技术新材料分会会长杨蓉娅、同济医院 整形美容外科主任崔海燕、北京键凯科技股份有限公司(以下简称"键凯科技"，股票代码：688356.SH) 董事长赵宣、天津泰达医药健康产业促进局副局长王泳江、键凯科技医美总监王辰、中国医学科学院整 形外科医院原注射美容中心主任陈光宇、华西医院整形烧伤科博士生导师李正勇副主任、江西省人民医 院整形颌面外科主任刘诚、北京首玺丽格医疗美容诊所院长韩胜、北京博瑞娜医疗美容门诊部院长王博 等众多权威专家到场，共同见证国内首款拥有完全自主知识产权的PEG交联透明质酸钠凝胶的上市里程 碑时刻。 核心技术突围：PEG交联成全场焦点 发布会上，丝玫瑰的核心技术优势备受瞩目。键凯科技医美事业部总监王辰先生详细解读了PEG交联技 术的创新突破：相较于传统产品，丝玫瑰的PEG交联结构构建了更丰富的三维空间网络，赋予产品良好 的柔弹性，能让静动态表情自然融合，有效避免移位变形问题。 圆桌会落幕后迎来战略合作签约与新品上市两大核心环节。键凯科技与华润 ...